Kiromic BioPharma (OTCPK:KRBP) - Stock Price, News & Analysis

KRBP Stock Overview

A clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. More details

KRBP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 18% per year over past 5 years

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($1M)

Has less than 1 year of cash runway

+ 3 more risks

Kiromic BioPharma, Inc. Competitors

Allarity Therapeutics

NasdaqCM:ALLR

US$4.9m

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$2.2m

Entero Therapeutics

NasdaqCM:ENTO

US$2.3m

GRI Bio

NasdaqCM:GRI

US$6.1m

Price History & Performance

Summary of all time highs, changes and price drops for Kiromic BioPharma
Historical stock prices
Current Share Price	US$0.91
52 Week High	US$3.78
52 Week Low	US$0.18
Beta	1.98
11 Month Change	-20.87%
3 Month Change	-56.46%
1 Year Change	313.64%
33 Year Change	-98.68%
5 Year Change	n/a
Change since IPO	-99.74%

Recent updates

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Oct 06

Shareholder Returns

	KRBP	US Biotechs	US Market
7D	-16.5%	2.5%	1.0%
1Y	313.6%	15.6%	31.4%

Return vs Industry: KRBP exceeded the US Biotechs industry which returned 15.6% over the past year.

Return vs Market: KRBP exceeded the US Market which returned 30.7% over the past year.

Price Volatility

Is KRBP's price volatile compared to industry and market?
KRBP volatility
KRBP Average Weekly Movement	30.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: KRBP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: KRBP's weekly volatility (30%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	35	Pietro Bersani	kiromic.com

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L.

Kiromic BioPharma, Inc. Fundamentals Summary

How do Kiromic BioPharma's earnings and revenue compare to its market cap?
KRBP fundamental statistics
Market cap	US$1.41m
Earnings (TTM)	-US$30.58m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is KRBP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KRBP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$30.58m
Earnings	-US$30.58m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-19.78
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-146.9%

How did KRBP perform over the long term?

See historical performance and comparison

KRBP Stock Overview

Risk Analysis

Kiromic BioPharma, Inc. Competitors

NasdaqCM:ALLR

US$4.9m

NasdaqCM:SONN

US$2.2m

NasdaqCM:ENTO

US$2.3m

NasdaqCM:GRI

US$6.1m

Price History & Performance

Recent News & Updates

Kiromic BioPharma, Inc. Reports Favorable Ongoing Clinical Results from Fourth and Sixth Patients Enrolled in Deltacel-01

Kiromic Biopharma Advances Deltacel-01 into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation

Kiromic Biopharma’s Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma, Inc. Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Recent updates

Kiromic BioPharma, Inc. Reports Favorable Ongoing Clinical Results from Fourth and Sixth Patients Enrolled in Deltacel-01

Kiromic Biopharma Advances Deltacel-01 into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation

Kiromic Biopharma’s Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma, Inc. Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Less than half of directors are independent

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic expands in-house cell therapy manufacturing facility, names new COO

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

New 90-day high: US$11.81

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

New 90-day high: US$10.45

Kiromic Announces License Agreement With Longwood University for chPD1

Kiromic BioPharma, Inc. Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

Kiromic BioPharma, Inc. Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA

Kiromic BioPharma files two IND applications for CAR-T therapy in cancer